Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

RNA Therapeutics – The Next Generation of Drugs for Cardiovascular Diseases

Version 1 : Received: 10 December 2021 / Approved: 16 December 2021 / Online: 16 December 2021 (14:07:05 CET)

A peer-reviewed article of this Preprint also exists.

Journal reference: Curr Atheroscler Rep 2022
DOI: 10.1007/s11883-022-01007-9


Abstract Purpose of review: RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella. Recent findings:RNA therapeutics are designed to regulate gene expression in a transient manner. For example, depending upon the strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. RNA therapies include antisense nucleotides, microRNAs and small interfering RNAs, RNA aptamers, and messenger RNAs. Further, we discuss the mechanism(s) by which different RNA therapies either reduce or increase the expression of their targets. Summary: We review the RNA therapeutics approved (and those in trials) to treat cardiovascular indications. RNA-based therapeutics are a new, rapidly growing class of drugs that will offer new alternatives for an increasing array of cardiovascular conditions.


RNA therapeutics; cardiovascular disease; mRNA therapeutics; siRNA therapeutics; antisense oligonucleotide therapeutics



Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.